CurrentUnitedHealthcarePolicy CS085KY.13

Cell Free Fetal Dna Testing Ky Cs

UnitedHealthcare Medical Policy CS085KY.13 governs use of cell-free fetal DNA testing for prenatal screening in Kentucky, specifying medical necessity for RhD/alloimmunization indications and listing tests/indications considered unproven or not medically necessary (expanded panels, genome-/exome-wide testing, twin zygosity, microdeletions/CNVs, single-gene disorders, fetal antigens other than RhD).

Policy Summary

PayerUnitedHealthcare

PolicyCell Free Fetal Dna Testing Ky Cs

Policy CodePolicy CS085KY.13

Change TypeAdded proven RhD/allocation criteriaremoved some prior proven trisomy screening languagerevised unproven indications

Effective DateAug 1, 2025

Next Review Date

Key ActionDocument that invasive diagnostic testing was offered and declined and ensure all required clinical criteria for RhD/alloimmunization are met for coverage.

SourceLink

POLICY UPDATE CHANGES

Added language indicating Cell-Free Fetal DNA testing using maternal plasma to determine fetal genotype is proven and medically necessary when the individual is alloimmunized or at risk for alloimmunization and all specified conditions are met.

Added language that cfDNA testing is proven and medically necessary when the individual undergoing testing is alloimmunized or at risk for alloimmunization due to maternal RhD status or red cell antigen antibodies, and all specified criteria are met.

Removed language indicating DNA-based noninvasive prenatal tests were proven and medically necessary as screening tools for trisomies 21, 18, and 13 under multiple prior-specified circumstances.

Removed Vanadis® designation (previously listed as unproven and not medically necessary).

Replaced general statement that DNA-based noninvasive prenatal tests are unproven for all other indications with a narrower statement: cfDNA using maternal plasma is unproven and not medically necessary for indications beyond screening for trisomies 21, 18, 13, and sex chromosomes, including expanded panels.

Removed CPT codes 0327U, 81420, and 81507 from applicable codes.

Removed an extensive list of applicable ICD-10 diagnosis codes from the policy.

Removed the definition of Massively Parallel Sequencing (MPS) from Definitions section.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

1State-specific policy (Kentucky)

1Covered specific indication (RhD/alloimmunization)

6Listed unproven/not medically necessary indications

0.71%High-risk CNV detection rate (Xue et al. 2022)

38.42%Overall PPV for CNV detection (Xue et al. 2022)

75%Sensitivity for 22q11.2 detection (Dar et al. 2022)

99.84%Specificity for 22q11.2 detection (Dar et al. 2022)

3Removed CPT codes

~150Removed ICD-10 codes (approximate list count)

Coverage Summary

Policy CS085KY.13 (effective August 1, 2025) governs Cell‑Free Fetal DNA (cffDNA / cfDNA / NIPT) testing for prenatal screening for UnitedHealthcare members in Kentucky only. The policy emphasizes a state‑specific application and requires providers to verify Kentucky coverage and prior authorization requirements.

Scope focuses on defining a proven medically necessary indication limited to fetal genotype testing for RhD/alloimmunization risk when all required criteria are met, and a broad set of uses that are considered unproven and not medically necessary (including expanded panels, genome/exome‑wide testing, twin zygosity, CNVs/microdeletions, single‑gene disorders, and fetal antigen testing other than RhD).

High‑level coverage stance is mixed: specific RhD/alloimmunization fetal genotype testing is covered when all criteria are met (including documentation that invasive diagnostic testing was offered and declined and paternal heterozygosity or unknown status), while many expanded or non‑routine indications are designated as unproven / not medically necessary.

Key thresholds and quick facts

Gestational age thresholdAs early as 10 weeks gestation (some RhD assays reported beginning at 9 weeks)

CNV size PPV thresholdHigher PPV for CNVs >10 Mb (e.g., 46.5%) vs ≤10 Mb (28.57%)

Fetal fraction noteLow fetal fraction often causes no‑call results; some algorithms evaluate paternally inherited haplotype only for FF ~2.8–6.5%

New proven indicationFetal genotype testing for RhD/alloimmunization is now a covered proven indication (added 08/01/2025)

New unproven categoryExpanded cfDNA panels (testing beyond trisomies 21,18,13 and sex chromosomes) newly listed as unproven/not medically necessary

Medically Necessary and Coverage Criteria

Medically Necessary - RhD / Alloimmunization Indication

Covered when ALL of the following are met:

ref

title

ref_orig

title_orig

ref_duplicate_removed

ref

Unproven and Not Medically Necessary Indications

Coding

Applicable Procedure / Molecular Codes (reference only)mixed

0060U	Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood.
0488U	Obstetrics (fetal antigen noninvasive prenatal test), cell-free DNA sequence analysis for detection of fetal presence or absence of 1 or more of the Rh, C, c, D, E, Duffy (Fya), or Kell (K) antigen in alloimmunized pregnancies, reported as selected antigen(s) detected or not detected.
0489U	Obstetrics (single-gene noninvasive prenatal test), cell-free DNA sequence analysis of 1 or more targets (e.g., CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants, and relative mutation-dosage analysis based on molecular counts to determine fetal inheritance of maternal mutation, algorithm reported as a fetal risk score for the condition (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia).
0494U	Red blood cell antigen (fetal RhD gene analysis), next-generation sequencing of circulating cell-free DNA (cfDNA) of blood in pregnant individuals known to be RhD negative, reported as positive or negative.
0536U	Red blood cell antigen (fetal RhD), PCR analysis of exon 4 of RHD gene and housekeeping control gene GAPDH from whole blood in pregnant individuals at 10+ weeks gestation known to be RhD negative, reported as fetal RhD status.
81422	Fetal chromosomal microdeletion(s) genomic sequence analysis (e.g., DiGeorge syndrome, Cri-du-chat syndrome), circulating cell-free fetal DNA in maternal blood.
81479	Unlisted molecular pathology procedure

Removed CPT codesCPTNot Covered

0327U	Description per policy brief: (use brief code_groups[1] descriptions).
81420	Cell-free DNA testing for common aneuploidies (policy brief removal list).
81507	Unlisted molecular pathology procedure (removed).

Removed ICD-10 diagnosis codesICD-10Not Covered

O35.IX	Maternal care for (suspected) fetal abnormality and damage, unspecified fetus; code removed effective 08/01/2025.
X0	(Placeholder) code O35.IX X0 — preserved from source; removed from policy effective 08/01/2025.

Provider Actions & Requirements

Documentation Required

Offer of invasive diagnostic testing must be documented

Invasive diagnostic testing (e.g., amniocentesis or chorionic villus sampling) must be offered to the member and the member’s decision to decline must be documented in the medical record prior to ordering noninvasive fetal genotyping. Documentation of the offer and decline should be available on request.

Examples of acceptable documentation: clinician note documenting that invasive testing was offered and declined, signed informed refusal form, genetic counseling note indicating offer of diagnostic testing and patient decision.

Prior Authorization

Coverage limited to alloimmunized or at-risk individuals with paternal heterozygosity/unknown status and declined invasive testing

Coverage is limited to alloimmunized individuals or those at risk for alloimmunization when paternal heterozygosity for the relevant antigen is demonstrated or paternal status is unknown, and when indicated invasive diagnostic testing has been offered and declined. Prior authorization requirements apply only when all required clinical criteria are documented in the medical record and submitted with the prior authorization request.

Clinical Evidence Summaries and Implications

Evidence syntheses and individual studies show variable analytic and clinical performance across different expanded cfDNA applications, with implications for interpretation and clinical utility rather than uniform test reliability.

For detection of subchromosomal CNVs and microdeletions, large prospective and retrospective studies report moderate-to-low PPVs and variable sensitivity that depend on CNV size and assay: for example, Xue et al. (NIPT‑plus, 31,260 singletons) reported an overall PPV 38.42%, with PPV 46.5% for CNVs >10 Mb and 28.6% for ≤10 Mb, and other genome‑wide analyses document sensitivity reductions when out‑of‑scope CNVs are counted as false negatives. Multiple reviews (Hayes; systematic reviews/meta‑analyses) note high heterogeneity and frequent false positives for rare autosomal trisomies (RATs) with pooled PPVs often very low, underscoring limited utility for routine screening.

For specific syndromes such as 22q11.2 (DiGeorge), SNP‑based cfDNA studies demonstrate imperfect but clinically informative performance: Dar et al. reported sensitivity ~75%, specificity ~99.84%, and a PPV that improved from ~23.7% to ~52.6% with an updated algorithm, illustrating that algorithmic choices and prevalence materially affect predictive values. Other validation studies (mmPCR, retrospective commercial datasets) show high specificity but low estimated PPVs in general populations.

Single‑gene and targeted sgNIPT approaches show promising analytic sensitivity and specificity in selected, often higher‑risk or reflexed populations, but most studies have limited outcome ascertainment and possible manufacturer involvement. Examples include Wynn et al. (sgNIPT reflex workflow) reporting sensitivity 96%, specificity 95.2%, and average PPV ~50% in subsets with outcome data; however, low numbers of confirmed affected pregnancies and limited follow‑up temper conclusions about broad clinical utility.

For fetal antigen genotyping (beyond RhD), emerging NGS‑based analytic validations report very high sensitivity and specificity in constrained cohorts (for example, Rego/Alford report near‑100% analytic concordance in limited series), but authors and guideline panels caution that clinical outcome and impact data remain limited and potential conflicts of interest exist.

Definitions & FAQs

Aneuploidy: An abnormal number of chromosomes in a human cell (includes trisomy and monosomy).

Cell Free Fetal DNA (cffDNA / cfDNA): Small fragments of fetal DNA from the placenta circulating in maternal blood used for noninvasive prenatal screening.

Comparative Genomic Hybridization (CGH): A microarray technology to detect genomic copy number variations using labeled DNA hybridized to arrays.

NIPT / NIPS: Non‑Invasive Prenatal Testing/Screening; analysis of cffDNA for fetal aneuploidy and other genetic anomalies.

Twin Zygosity: Type of conception (dizygotic vs monozygotic twins).

Whole Genome Sequencing (WGS): Determines the sequence of the entire genome (coding and non‑coding regions).

cfDNA / NIPT (term restated): Maternal blood screening test analyzing fetal‑derived DNA fragments to assess risk for fetal chromosomal abnormalities; screening not diagnostic—definitive diagnosis requires invasive testing (CVS/amniocentesis).

CNV (Copy Number Variant): A deletion or duplication of genomic material that can be clinically significant depending on size and location.

PPV/NPV/DR: Positive predictive value / negative predictive value / detection rate (sensitivity).

Alloimmunization: Maternal immune response producing antibodies against fetal red cell antigens that can cause hemolytic disease of the fetus and newborn (HDFN).

FAQs: Q: Are expanded genome‑wide cfDNA screens equivalent to diagnostic testing? A: No. Expanded cfDNA screens are screening tests with variable sensitivity and PPV depending on the condition and CNV size; diagnostic confirmation (e.g., amniocentesis with chromosomal microarray) is required for positive results.

Revision History

2025-08-01added — criteria detail: Added three required conditions: alloimmunization/risk, paternal heterozygosity or unknown, and that invasive diagnostic testing was offered and declinedLatest

2025-08-01added — clarification: Clarifies coverage for fetal RhD/fetal genotype testing in alloimmunized or at-risk pregnanciesLatest

Policy Summary

PayerUnitedHealthcare

PolicyCell Free Fetal Dna Testing Ky Cs

Policy CodePolicy CS085KY.13

Change TypeAdded proven RhD/allocation criteriaremoved some prior proven trisomy screening languagerevised unproven indications

Effective DateAug 1, 2025

Next Review Date

Key ActionDocument that invasive diagnostic testing was offered and declined and ensure all required clinical criteria for RhD/alloimmunization are met for coverage.

SourceLink

On This Page

Prior authorization will be required when the member meets the coverage criteria and documentation of paternal genotype/unknown status and evidence that invasive testing was offered and declined is provided.

Documentation Required

Genetic counseling recommended

Genetic counseling is recommended both before testing to explain the limits of screening and after certain results to review implications and next steps.

Pretest counseling: Discuss advantages, limitations, and that cfDNA is a screening test (not diagnostic) and the potential need for diagnostic testing to confirm positive or uncertain results.
Post-test counseling: Provide genetic counseling for individuals with positive or no-call results to review increased risk, limitations of the screen, and diagnostic follow-up options.

Documentation Required

Confirmatory diagnostic testing required for screen-positive results

Screen-positive (or otherwise high-risk) cfDNA results must be confirmed with diagnostic testing (e.g., amniocentesis with chromosomal microarray or karyotype) before any irreversible clinical decision is made.

Confirmatory diagnostic testing (e.g., amniocentesis with microarray or CVS where appropriate) is required prior to pregnancy termination or other irreversible interventions.

Denial Risk

No-call results imply increased aneuploidy risk

A 'no-call' or failed cfDNA result is associated with an increased risk of aneuploidy and should prompt counseling and consideration of diagnostic testing or repeat testing as clinically appropriate.

Recommended follow-up for no-call results: offer genetic counseling, consider invasive diagnostic testing, or repeat cfDNA testing only after counseling about limitations and potential risks.

Prior Authorization

Policy applies to Kentucky membership

This policy applies only to UnitedHealthcare membership in Kentucky. Providers should verify state-specific coverage and prior authorization requirements for members in other states.

Verify member state of coverage and any state-specific PA requirements before ordering testing.

Overall implication: performance metrics (sensitivity, specificity, PPV) for expanded cfDNA testing vary widely by condition, assay methodology, cohort prevalence, and CNV size. Because PPV is strongly prevalence‑dependent and many positive cfDNA results (especially for RATs and some CNVs) reflect placental mosaicism rather than fetal involvement, confirmatory invasive diagnostic testing (e.g., amniocentesis with microarray) is required before definitive clinical decisions. Guideline and HTA assessments characterize evidence for many expanded uses as low quality or insufficient to establish clinical utility.

Study / Source	Key performance metrics / findings
Gilstrop et al. (2025) RhD NGS study	Sensitivity 100% (all 356 RhD+ fetuses identified); Specificity 99.3% (295/297 RhD- fetuses); PPV 98.4%; NPV ~100% beginning at 9 weeks gestation
Yang et al. (meta-analysis) (2019)	False negative rate 0.34% (95% CI 0.15-0.76); false positive rate 3.86% (95% CI 2.54-5.82) for RhD NIPT
Konya et al. (2024) genome-wide RATs meta-analysis	Pooled PPV using confirmed method 0.07; extended method 0.13; high heterogeneity (I2 ≈ 95%) — low PPV for RATs overall
Xue et al. (2022) CNV (NIPT-plus) study	0.71% high‑risk detection rate; overall PPV 38.42%; PPV 46.5% for CNVs >10 Mb vs 28.57% for ≤10 Mb; false positive rate 0.40%
Dar et al. (2022) 22q11.2 (SNP-based) multicenter study	Sensitivity 75%, Specificity 99.84%, PPV 23.7%, NPV 99.98%; updated algorithm improved PPV to 52.6%
Rego et al. (2025) fetal antigen (NGS quantitative) limited prospective cohort	465 antigen calls (K1, E, C, Fya, c, D): reported 100% sensitivity, 100% specificity, 100% accuracy vs neonatal genotype (limited cohort; potential manufacturer affiliations noted)
Wynn et al. (2023) sgNIPT (carrier screening reflex)	sgNIPT subset: sensitivity 96%, specificity 95.2%, average PPV 50%, NPV 99.8%; overall carrier‑screen reflex sensitivity 92.4%, specificity 99.9% (limited outcome data)
Professional society positions (ACOG, ACMG, ISPD, ASHG/ESHG, NICE, NSGC)	ACOG/ACMG/ISPD: cfDNA recommended for common trisomies; ACMG conditional/limited support for 22q11.2; societies note insufficient evidence for routine RAT/CNV/expanded/single‑gene screening; ACOG: cfDNA reasonable alternative for fetal RHD in alloimmunized patients who decline amniocentesis; NICE recommends high‑throughput cfDNA for fetal RhD genotype (DG25)

Q: Can cfDNA reliably genotype fetal antigens other than RhD? A: Emerging NGS‑based studies report high analytic accuracy in limited cohorts, but larger validation and clinical outcome studies are still needed before routine adoption; evidence is encouraging but currently limited.

2025-08-01removed — prior proven indicationsLatest

Removed language indicating DNA-based noninvasive prenatal tests were proven and medically necessary as screening tools for trisomies 21, 18, and 13 under multiple prior-specified circumstances.

2025-08-01removed — CPT codesLatest

Removed CPT codes 0327U, 81420, and 81507 from applicable codes.

2025-08-01removed — ICD-10 codesLatest

Removed an extensive list of applicable ICD-10 diagnosis codes from the policy.

2025-08-01revised — unproven indications (added expanded panel)Latest

2025-08-01removed — Vanadis® designation (administrative)Latest

Removed Vanadis® designation (previously listed as unproven and not medically necessary).

2025-08-01removed — definitions cleanupLatest

Removed the definition of Massively Parallel Sequencing (MPS) from Definitions section.